QUANTUM-SI INC
QSINASDAQTrading Snapshot
- Day Range
- $1.06 – $1.09
- 52-Week Range
- $0.69 – $3.10
- Volume
- $3.77B
- Avg Volume
- $3.08B
- Shares Outstanding
- 197.8M
- Next Earnings
- Oct 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $344,000
- P/E Ratio
- -1.7
- P/S Ratio
- 98.0x
- EPS (TTM)
- $-0.45
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +35.2%
Why Investors Own QSI
- ✓High-growth profile — revenue up +6.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 38% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
QUANTUM-SI INC
QSI
StockOtter · stockotter.spaceAbout QUANTUM-SI INC
Quantum-Si incorporated operates within the life sciences sector, focusing on the creation of an advanced platform for individual molecule detection. This innovative technology is designed to streamline sample preparation and subsequent sequencing processes. The company offers a unique, proprietary single molecule detection system that draws on advancements from the semiconductor industry. This system is specifically applied to the field of proteomics, paving the way for next-generation protein sequencing. Established in 2013, Quantum-Si's headquarters are located in Guilford, Connecticut.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro
BRANFORD, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencin
Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™
BRANFORD, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencin
Quantum-Si Expands Proteus™ Roadshow with Additional U.S. and European Cities
BRANFORD, Conn., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule protei
Quantum-Si to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
BRANFORD, Conn., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule protein
Quantum-Si incorporated (QSI) Q2 2026 Earnings Call Transcript
Quantum-Si incorporated (QSI) Q2 2026 Earnings Call Transcript
Quantum-Si Q2 Earnings Call Highlights
Quantum-Si NASDAQ: QSI said it has moved the planned launch of its Proteus protein sequencing platform to the second quarter of 2027 from the end of 2026, citing the need for an additional integrated instrument design cy